DE2547690B1 - Arzneimittel zur Behandlung von Affektionen der Schleimhaut,insbesondere von Parodontalerkrankungen - Google Patents
Arzneimittel zur Behandlung von Affektionen der Schleimhaut,insbesondere von ParodontalerkrankungenInfo
- Publication number
- DE2547690B1 DE2547690B1 DE2547690A DE2547690A DE2547690B1 DE 2547690 B1 DE2547690 B1 DE 2547690B1 DE 2547690 A DE2547690 A DE 2547690A DE 2547690 A DE2547690 A DE 2547690A DE 2547690 B1 DE2547690 B1 DE 2547690B1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- affections
- treatment
- medicines
- healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004400 mucous membrane Anatomy 0.000 title claims description 9
- 239000003814 drug Substances 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims description 5
- 208000028169 periodontal disease Diseases 0.000 title description 5
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- 239000003918 blood extract Substances 0.000 claims description 14
- 239000003883 ointment base Substances 0.000 claims description 13
- 230000003444 anaesthetic effect Effects 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 6
- GNZIHPAAJVXCAS-UHFFFAOYSA-N quinolin-4-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=CC=NC2=C1 GNZIHPAAJVXCAS-UHFFFAOYSA-N 0.000 claims description 3
- 230000035876 healing Effects 0.000 description 11
- 239000002674 ointment Substances 0.000 description 9
- 230000036407 pain Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 208000002399 aphthous stomatitis Diseases 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000019477 peppermint oil Nutrition 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- GHSCYMOJHVOGDJ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-hydroxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1O GHSCYMOJHVOGDJ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010057371 Hypoaesthesia oral Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035620 dolor Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2547690A DE2547690B1 (de) | 1975-10-24 | 1975-10-24 | Arzneimittel zur Behandlung von Affektionen der Schleimhaut,insbesondere von Parodontalerkrankungen |
| FR7631938A FR2328477A1 (fr) | 1975-10-24 | 1976-10-22 | Medicament pour le traitement d'affections des muqueuses, en particulier des maladies parodontales |
| BE171754A BE847587A (fr) | 1975-10-24 | 1976-10-22 | Medicament pour le traitement d'affections des muqueuses, en particulier des maladies parodontales |
| JP51126383A JPS5270009A (en) | 1975-10-24 | 1976-10-22 | Curing agent for mucous |
| NL7611708A NL7611708A (nl) | 1975-10-24 | 1976-10-22 | Werkwijze voor het bereiden van een geneesmiddel ter behandeling van slijmvliesaandoeningen, in het bijzonder parodontale ziekten. |
| GB44036/76A GB1553088A (en) | 1975-10-24 | 1976-10-22 | Pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2547690A DE2547690B1 (de) | 1975-10-24 | 1975-10-24 | Arzneimittel zur Behandlung von Affektionen der Schleimhaut,insbesondere von Parodontalerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2547690B1 true DE2547690B1 (de) | 1977-02-10 |
Family
ID=5960036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2547690A Withdrawn DE2547690B1 (de) | 1975-10-24 | 1975-10-24 | Arzneimittel zur Behandlung von Affektionen der Schleimhaut,insbesondere von Parodontalerkrankungen |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5270009A (enExample) |
| BE (1) | BE847587A (enExample) |
| DE (1) | DE2547690B1 (enExample) |
| FR (1) | FR2328477A1 (enExample) |
| GB (1) | GB1553088A (enExample) |
| NL (1) | NL7611708A (enExample) |
-
1975
- 1975-10-24 DE DE2547690A patent/DE2547690B1/de not_active Withdrawn
-
1976
- 1976-10-22 NL NL7611708A patent/NL7611708A/xx not_active Application Discontinuation
- 1976-10-22 JP JP51126383A patent/JPS5270009A/ja active Pending
- 1976-10-22 GB GB44036/76A patent/GB1553088A/en not_active Expired
- 1976-10-22 BE BE171754A patent/BE847587A/xx not_active IP Right Cessation
- 1976-10-22 FR FR7631938A patent/FR2328477A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB1553088A (en) | 1979-09-19 |
| JPS5270009A (en) | 1977-06-10 |
| NL7611708A (nl) | 1977-04-26 |
| FR2328477B1 (enExample) | 1980-04-30 |
| FR2328477A1 (fr) | 1977-05-20 |
| BE847587A (fr) | 1977-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69430903T2 (de) | Behandlung von periodontitis mit misoprostol | |
| DE3750836T2 (de) | Zwei-stufen-verfahren zur heilung schmerzenfreier wunden, sowie wässriges medium und topische salbe zur verwendung dazu. | |
| DE3856018T2 (de) | Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung | |
| DE60109044T2 (de) | Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms | |
| DE69621132T2 (de) | Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa | |
| EP0307599A1 (de) | Arzneimittel für den Bereich der Mundhöhle | |
| DE60112431T2 (de) | Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments | |
| DE69614375T2 (de) | Dermatologische zubereitung zur behandlung von aktinischen keratosen | |
| DE69825279T2 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| EP0037488A2 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
| EP0285856B1 (de) | Verwendung von Dihydroergotamin und seinen Salzen zur lokalen Behandlung trophischer Störungen | |
| DE69730214T2 (de) | Zusammensetzung und verfahren zur behandlung von herpes simplex | |
| WO2003041723A1 (de) | Pharmazeutische anwendungen von hyaluronsäure-präparaten | |
| DD273977A5 (de) | Verfahren zur herstellung eines stomatologischen praeparates | |
| DE69801820T2 (de) | Verwendung von Dichlorobenzyl Alkohol zur Herstellung einer Zusammenstellung zur topischen Behandlung von Entzündungen | |
| DE3443242A1 (de) | Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel | |
| DE1917283C3 (de) | Herstellung antimikrobieller Präparate | |
| US4466956A (en) | Method of therapy for oral herpes simplex | |
| WO1994011009A1 (de) | Zusammensetzung zur bekämpfung von dermatomykosen und deren erregern sowie von schweissbildung und körpergeruch | |
| DE2547690B1 (de) | Arzneimittel zur Behandlung von Affektionen der Schleimhaut,insbesondere von Parodontalerkrankungen | |
| DE3827953C2 (enExample) | ||
| DE2015877C3 (de) | Arzneimittel zur Behandlung der Prostatahypertrophie | |
| DE4434929A1 (de) | Nystatin-Haftsalbe | |
| DE1667891A1 (de) | Neue therapeutische Zusammensetzungen mit analgetischer Wirksamkeit | |
| DE102012000416A1 (de) | Zusammensetzung für die topische Applikation II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BHN | Withdrawal |